- Home
- ATEN vs ORKA Comparison
ATEN vs ORKA Comparison
Compare ATEN & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEN
- ORKA
- Stock Information
- Founded
- ATEN 2004
- ORKA 2004
- Country
- ATEN United States
- ORKA United States
- Employees
- ATEN N/A
- ORKA N/A
- Industry
- ATEN EDP Services
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATEN Technology
- ORKA Health Care
- Exchange
- ATEN Nasdaq
- ORKA Nasdaq
- Market Cap
- ATEN 1.4B
- ORKA 354.2M
- IPO Year
- ATEN 2014
- ORKA N/A
- Fundamental
- Price
- ATEN $18.33
- ORKA $14.21
- Analyst Decision
- ATEN Strong Buy
- ORKA Strong Buy
- Analyst Count
- ATEN 3
- ORKA 8
- Target Price
- ATEN $21.33
- ORKA $39.71
- AVG Volume (30 Days)
- ATEN 830.0K
- ORKA 360.1K
- Earning Date
- ATEN 08-05-2025
- ORKA 08-15-2025
- Dividend Yield
- ATEN 1.31%
- ORKA N/A
- EPS Growth
- ATEN 9.85
- ORKA N/A
- EPS
- ATEN 0.67
- ORKA N/A
- Revenue
- ATEN $267,158,000.00
- ORKA N/A
- Revenue This Year
- ATEN $9.40
- ORKA N/A
- Revenue Next Year
- ATEN $7.66
- ORKA N/A
- P/E Ratio
- ATEN $27.25
- ORKA N/A
- Revenue Growth
- ATEN 4.90
- ORKA N/A
- 52 Week Low
- ATEN $12.27
- ORKA $5.49
- 52 Week High
- ATEN $21.90
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- ATEN 46.76
- ORKA N/A
- Support Level
- ATEN $19.19
- ORKA N/A
- Resistance Level
- ATEN $20.28
- ORKA N/A
- Average True Range (ATR)
- ATEN 0.51
- ORKA 0.00
- MACD
- ATEN -0.08
- ORKA 0.00
- Stochastic Oscillator
- ATEN 32.85
- ORKA 0.00
About ATEN A10 Networks Inc.
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.